| 139 | |
| Summary | Gut microbes (species: Eggerthella lenta) decrease Levodopa's bioavailability. |
| Gut | |
| Levodopa (PubChem CID: 6047) | |
| Eggerthella lenta (Tax ID: 84112) | |
| 31196984 | |
| decrease bioavailability | |
| Levodopa, antiparkinson's drug, needs to be activated to dopamine after crossing the blood-brain barrier peripheral conversion to dopamine results in many side effects. The gut microbiota mainly Enterococcus faecalis can metabolize levodopa peripherally. Enterococcus faecalis metabolizes levodopa by a pyridoxal phosphate-dependent tyrosine decarboxylase to dopamine. further conversion of dopamine to m-tyramine by Eggerthella lenta. |
Browse Drug-Microbiome Relationship
Home